Baseline characteristics and response to retreatment grouped by initial response to IMiD
| . | Len→Len* n = 48 . | Len→Thal* n = 11 . | Thal→Len* n = 58 . | Thal→Thal* n = 23 . |
|---|---|---|---|---|
| Median age, y (range) | 63 (29-78) | 58 (33-72) | 60 (38-77) | 57 (38-71) |
| Males, % | 58 | 55 | 62 | 74 |
| High-risk MM, n (%) | 6 (13) | 2 (18) | 12 (21) | 3 (13) |
| Median no. of prior treatments | 2 | 1 | 2 | 2 |
| SCT before repeat IMiD, % | 79 | 55 | 71 | 87 |
| Dex plus repeat IMiD, % | 92 | 100 | 86 | 87 |
| Median duration of first IMiD, mo (IQR) | 4 (4-6) | 5 (4-8) | 4 (3-6) | 4 (3-5) |
| Median time from diagnosis to repeat IMiD, mo (IQR) | 26 (18-38) | 13 (4-23) | 31 (23-49) | 23 (18-36) |
| Median duration of second IMiD, mo (IQR) | 7 (3-18) | 3 (2-4) | 7 (3-14) | 6 (2-18) |
| Response to first-line IMiD† | ||||
| ≥ VGPR(%)† | 5 ≥ VGPR (45) | 1 PR (33) | 2 ≥ VGPR (33) | 1 PR (25) |
| 3 PR (27) | 2 < PR (67) | 1 PR (17) | 3 < PR (75) | |
| 3 < PR (27) | 3 < PR (50) | |||
| PR (%)† | 4 ≥ VGPR (18) | 1 ≥ VGPR (25) | 2 ≥ VGPR (8) | 5 PR (45) |
| 7 PR (32) | 3 < PR (75) | 7 PR (29) | 6 < PR (55) | |
| 11 < PR (50) | 15 < PR (63) | |||
| < PR (%)‡ | 2 ≥ VGPR (33) | 3 < PR (100) | 1 ≥ VGPR (7) | 5 < PR (100) |
| 4 < PR (67) | 8 PR (57) | |||
| 5 < PR (36) | ||||
| ORR (> PR)‡ (n = 140), % | 54 | 20 | 48 | 30 |
| N§ | 44 (92%) | 7 (64%) | 50 (86%) | 22 (96%) |
| RR§ (n = 123; 88%)‡, % | 57 | 17 | 47 | 32 |
| N‖ | 4 (8%) | 4 (36%) | 8 (14%) | 1 (4%) |
| RR‖ (n = 17; 12%)‡, % | 25 | 25 | 50 | 0 |
| . | Len→Len* n = 48 . | Len→Thal* n = 11 . | Thal→Len* n = 58 . | Thal→Thal* n = 23 . |
|---|---|---|---|---|
| Median age, y (range) | 63 (29-78) | 58 (33-72) | 60 (38-77) | 57 (38-71) |
| Males, % | 58 | 55 | 62 | 74 |
| High-risk MM, n (%) | 6 (13) | 2 (18) | 12 (21) | 3 (13) |
| Median no. of prior treatments | 2 | 1 | 2 | 2 |
| SCT before repeat IMiD, % | 79 | 55 | 71 | 87 |
| Dex plus repeat IMiD, % | 92 | 100 | 86 | 87 |
| Median duration of first IMiD, mo (IQR) | 4 (4-6) | 5 (4-8) | 4 (3-6) | 4 (3-5) |
| Median time from diagnosis to repeat IMiD, mo (IQR) | 26 (18-38) | 13 (4-23) | 31 (23-49) | 23 (18-36) |
| Median duration of second IMiD, mo (IQR) | 7 (3-18) | 3 (2-4) | 7 (3-14) | 6 (2-18) |
| Response to first-line IMiD† | ||||
| ≥ VGPR(%)† | 5 ≥ VGPR (45) | 1 PR (33) | 2 ≥ VGPR (33) | 1 PR (25) |
| 3 PR (27) | 2 < PR (67) | 1 PR (17) | 3 < PR (75) | |
| 3 < PR (27) | 3 < PR (50) | |||
| PR (%)† | 4 ≥ VGPR (18) | 1 ≥ VGPR (25) | 2 ≥ VGPR (8) | 5 PR (45) |
| 7 PR (32) | 3 < PR (75) | 7 PR (29) | 6 < PR (55) | |
| 11 < PR (50) | 15 < PR (63) | |||
| < PR (%)‡ | 2 ≥ VGPR (33) | 3 < PR (100) | 1 ≥ VGPR (7) | 5 < PR (100) |
| 4 < PR (67) | 8 PR (57) | |||
| 5 < PR (36) | ||||
| ORR (> PR)‡ (n = 140), % | 54 | 20 | 48 | 30 |
| N§ | 44 (92%) | 7 (64%) | 50 (86%) | 22 (96%) |
| RR§ (n = 123; 88%)‡, % | 57 | 17 | 47 | 32 |
| N‖ | 4 (8%) | 4 (36%) | 8 (14%) | 1 (4%) |
| RR‖ (n = 17; 12%)‡, % | 25 | 25 | 50 | 0 |
≥ VGPR includes patients with complete response; VGPR and < PR includes patients with stable and progressive disease and nonevaluable (n = 9) patients after first-line IMiD. High-risk multiple myeloma was determined by fluorescent in situ hybridization and conventional cytogenetics risk stratification of myeloma.
Thal indicates thalidomide; Len, lenalidomide; Dex, dexamethasone; IQR, interquartile range; ≥ VGPR, very good partial response; PR, partial response; ORR, overall response rate; and RR, response to retreatment.
Primary-salvage IMiD combination.
Response to retreatment with an IMiD is grouped by initial response to IMiD.
Patients with nonevaluable disease response (n = 27) were not used to calculate the percentage.
Number of patients and response rate among patients who discontinued first-line IMiD for reasons other than disease progression (transplant, toxicity, choice, and alternative treatment).
Number of patients and response rate among patients who discontinued first-line IMiD because of disease progression.